Two Sigma Investments
KRYS icon

Two Sigma Investments’s Krystal Biotech KRYS Stock Holding History

Two Sigma Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,683
Closed -$558K – 4586
2021
Q3 		$558K Buy
+10,683
New +$632K ﹤0.01% 3159
2020
Q3 		– Sell
-6,653
Closed -$276K – 3334
2020
Q2 		$276K Buy
+6,653
New +$320K ﹤0.01% 2437

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's KRYS Position: Q4 2021 in Review

Two Sigma Investments sold out of Krystal Biotech (KRYS) in Q4 2021, closing a stake of 10,683 shares — an estimated $558K sold.

Two Sigma Investments first reported a position in KRYS in Q2 2020 and held it in 2 quarters. The position peaked at $558K in Q3 2021. 140 funds tracked by Wall St. Rank hold KRYS as of Q4 2021.

  • Two Sigma Investments reported no remaining Krystal Biotech position as of Q4 2021 after selling out during the quarter.
  • Two Sigma Investments sold 10,683 Krystal Biotech shares in Q4 2021, an estimated $558K.
  • Two Sigma Investments first reported a position in Krystal Biotech in Q2 2020 and held it in 2 quarters.
  • Two Sigma Investments's Krystal Biotech position peaked at $558K in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2021.

Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.